Parexel Establishes New Location in Peru
PAREXEL, a global biopharmaceutical services provider, today announced that it has opened an office in Lima, Peru to provide regulatory consulting and clinical research capabilities.
PAREXEL STRENGHTHENS LEADING PRESENCE IN LATIN AMERICA WITH A NEW LOCATION IN PERU
Boston, MA, November 20, 2008—PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has opened an office in Lima, Peru to provide regulatory consulting and clinical research capabilities. With the addition of the Peru office, PAREXEL now has locations throughout five important biopharmaceutical centers in Latin America, which also include Argentina, Brazil, Chile, and Mexico. This expansion further strengthens the Company's position as one of the largest biopharmaceutical services providers in this emerging region for clinical development.
"PAREXEL has had a presence in Latin America since 1997, and a long-term commitment to providing clients with high quality services in the region. Due to the increasing globalization of clinical research, client demand for our capabilities in Latin America has been steadily increasing, and over the last seven years PAREXEL has experienced double-digit growth in the region. Peru is a key growing market in Latin America, with approximately 28 million people. The opening of our Peru office marks a significant opportunity for clients to further expand their clinical development programs throughout Latin America,” said Josef H. von Rickenbach, Chairman and Chief Executive Officer of PAREXEL. "Our experts in Latin America manage complex clinical trials on a regional and worldwide scale. Included among the broad array of services we provide, we are helping clients to navigate regulatory environments, identify qualified investigators, and access diverse patient populations throughout the region.”
Capabilities provided by PAREXEL's Latin American locations include regulatory advice for clinical development, as well as a broad range of services including project management, site management, data management, medical affairs, biostatistics, and bioanalysis for the conduct of Phase II-IV studies. PAREXEL's clinical logistics team in Latin America, with in-depth expertise in import and export regulations, coordinates multinational logistics and helps clients effectively manage global clinical trial supply requirements. PAREXEL's Latin American locations offer extensive late phase development capabilities including observational studies, patient registries, outcomes research, and expanded access programs.
For more information about PAREXEL's global Clinical Research Services, visit http://www.parexel.com/clinical_research.html.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
